Gilead Sciences’ Oncology M&A Strategy Explained

Gilead Sciences’ Oncology M&A Strategy Explained

Gilead Sciences (NASDAQ: GILD) has wanted to be a leader in cancer treatment for awhile, and this week, it made a big splash into the indication when it announced the planned acquisition of Kite Pharma (NASDAQ: KITE), a company developing a new platform for cancer treatment called CAR-T.

In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Michael Douglass is joined by Todd Campbell to discuss Gilead's oncology merger and acquisition (M&A) strategy. Watch the video below to find out if these industry watchers give this deal a "thumbs up."

A full transcript follows the video.

Continue reading

Source: Fool.com